{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T19:59:38Z","timestamp":1793131178134,"version":"4.5.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"DOI":"10.1186\/s12888-026-07858-9","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T11:23:51Z","timestamp":1770117831000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The prevalence of antipsychotic polypharmacy and its associations with violent behaviors among forensic psychiatry patients"],"prefix":"10.1186","volume":"26","author":[{"given":"Mark Mohan","family":"Kaggwa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Abaatyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praise","family":"Christi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Lessard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Bradford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary Andrew","family":"Chaimowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew Toyin","family":"Olagunju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"issue":"11","key":"7858_CR1","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/s2215-0366(24)00164-0","volume":"11","author":"J Tully","year":"2024","unstructured":"Tully J, Hafferty J, Whiting D, Dean K, Fazel S. Forensic mental health: envisioning a more empirical future. Lancet Psychiatry. 2024;11(11):934\u201342. https:\/\/doi.org\/10.1016\/s2215-0366(24)00164-0.","journal-title":"Lancet Psychiatry"},{"key":"7858_CR2","doi-asserted-by":"crossref","unstructured":"Siglag M. Innovative treatment approaches in forensic and correctional settings. London: Taylor & Francis; 2024.","DOI":"10.4324\/9781003360926"},{"key":"7858_CR3","doi-asserted-by":"publisher","first-page":"963","DOI":"10.3389\/fpsyt.2019.00963","volume":"10","author":"K Howner","year":"2019","unstructured":"Howner K, Andin\u00e9 P, Engberg G, Ekstr\u00f6m EH, Lindstr\u00f6m E, Nilsson M, Radovic S, Hultcrantz M. Pharmacological treatment in forensic Psychiatry-A systematic review. Front Psychiatry. 2019;10:963. https:\/\/doi.org\/10.3389\/fpsyt.2019.00963.","journal-title":"Front Psychiatry"},{"issue":"1","key":"7858_CR4","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1192\/bja.2021.34","volume":"28","author":"HG Kennedy","year":"2022","unstructured":"Kennedy HG. Models of care in forensic psychiatry. BJPsych Adv. 2022;28(1):46\u201359. https:\/\/doi.org\/10.1192\/bja.2021.34.","journal-title":"BJPsych Adv"},{"issue":"9","key":"7858_CR5","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1177\/0706743717720448","volume":"62","author":"G Remington","year":"2017","unstructured":"Remington G, Addington D, Honer W, Ismail Z, Raedler T, Teehan M. Guidelines for the pharmacotherapy of schizophrenia in adults. Can J Psychiatry. 2017;62(9):604\u201316. https:\/\/doi.org\/10.1177\/0706743717720448.","journal-title":"Can J Psychiatry"},{"issue":"9","key":"7858_CR6","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1177\/0706743717719894","volume":"62","author":"R Norman","year":"2017","unstructured":"Norman R, Lecomte T, Addington D, Anderson E. Canadian treatment guidelines on psychosocial treatment of schizophrenia in adults. Can J Psychiatry. 2017;62(9):617\u201323. https:\/\/doi.org\/10.1177\/0706743717719894.","journal-title":"Can J Psychiatry"},{"key":"7858_CR7","doi-asserted-by":"publisher","unstructured":"Reisegger A, Slamanig R, Winkler H, de Girolamo G, Carr\u00e0 G, Crocamo C, Gosek P, Heitzman J, Salize HJ, Picchioni M, et al. Pharmacological interventions to reduce violence in patients with schizophrenia in forensic psychiatry. CNS Spectr. 2021:1\u201311. https:\/\/doi.org\/10.1017\/s1092852921000134.","DOI":"10.1017\/s1092852921000134"},{"issue":"12","key":"7858_CR8","doi-asserted-by":"publisher","first-page":"5319","DOI":"10.1038\/s41380-023-02138-4","volume":"28","author":"M Solmi","year":"2023","unstructured":"Solmi M, Seitidis G, Mavridis D, Correll CU, Dragioti E, Guimond S, Tuominen L, Darg\u00e9l A, Carvalho AF, Fornaro M, et al. Incidence, prevalence, and global burden of schizophrenia - data, with critical appraisal, from the global burden of disease (GBD) 2019. Mol Psychiatry. 2023;28(12):5319\u201327. https:\/\/doi.org\/10.1038\/s41380-023-02138-4.","journal-title":"Mol Psychiatry"},{"issue":"3","key":"7858_CR9","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1108\/JFP-11-2017-0049","volume":"20","author":"M Dumont","year":"2018","unstructured":"Dumont M, Th\u00e9riault J, Briand C, Dumais A, Potvin S. Psychosocial approaches for individuals with schizophrenia in correctional and forensic psychiatric settings: A rapid review. J Forensic Pract. 2018;20(3):152\u201366. https:\/\/doi.org\/10.1108\/JFP-11-2017-0049.","journal-title":"J Forensic Pract"},{"issue":"12","key":"7858_CR10","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.2165\/11596930-000000000-00000","volume":"25","author":"L Citrome","year":"2011","unstructured":"Citrome L, Volavka J. Pharmacological management of acute and persistent aggression in forensic psychiatry settings. CNS Drugs. 2011;25(12):1009\u201321. https:\/\/doi.org\/10.2165\/11596930-000000000-00000.","journal-title":"CNS Drugs"},{"issue":"1","key":"7858_CR11","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/wps.20706","volume":"19","author":"W Gaebel","year":"2020","unstructured":"Gaebel W, Falkai P, Hasan A. The revised German evidence- and consensus-based schizophrenia guideline. World Psychiatry. 2020;19(1):117\u20139. https:\/\/doi.org\/10.1002\/wps.20706.","journal-title":"World Psychiatry"},{"issue":"12","key":"7858_CR12","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/s2215-0366(24)00314-6","volume":"11","author":"M H\u00f8jlund","year":"2024","unstructured":"H\u00f8jlund M, K\u00f6hler-Forsberg O, Gregersen AT, Rohde C, Mellentin AI, Anh\u00f8j SJ, Kemp AF, Fuglsang NB, Wiuff AC, Nissen L, et al. Prevalence, correlates, tolerability-related outcomes, and efficacy-related outcomes of antipsychotic polypharmacy: a systematic review and meta-analysis. Lancet Psychiatry. 2024;11(12):975\u201389. https:\/\/doi.org\/10.1016\/s2215-0366(24)00314-6.","journal-title":"Lancet Psychiatry"},{"issue":"12","key":"7858_CR13","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/S2215-0366(24)00367-5","volume":"11","author":"J Tiihonen","year":"2024","unstructured":"Tiihonen J, Taipale H. The challenges of antipsychotic polypharmacy. Lancet Psychiatry. 2024;11(12):945\u20136. https:\/\/doi.org\/10.1016\/S2215-0366(24)00367-5.","journal-title":"Lancet Psychiatry"},{"issue":"7","key":"7858_CR14","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1017\/s1461145712000399","volume":"17","author":"WW Fleischhacker","year":"2014","unstructured":"Fleischhacker WW, Uchida H. Critical review of antipsychotic polypharmacy in the treatment of schizophrenia. Int J Neuropsychopharmacol. 2014;17(7):1083\u201393. https:\/\/doi.org\/10.1017\/s1461145712000399.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"5","key":"7858_CR15","doi-asserted-by":"publisher","first-page":"383","DOI":"10.2165\/11587810-000000000-00000","volume":"25","author":"TR Barnes","year":"2011","unstructured":"Barnes TR, Paton C. Antipsychotic polypharmacy in schizophrenia: benefits and risks. CNS Drugs. 2011;25(5):383\u201399. https:\/\/doi.org\/10.2165\/11587810-000000000-00000.","journal-title":"CNS Drugs"},{"issue":"1","key":"7858_CR16","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s11126-017-9521-z","volume":"89","author":"K Patchan","year":"2018","unstructured":"Patchan K, Vyas G, Hackman AL, Mackowick M, Richardson CM, Love RC, Wonodi I, Sayer MA, Glassman M, Feldman S, et al. Clozapine in reducing aggression and violence in forensic populations. Psychiatr Q. 2018;89(1):157\u201368. https:\/\/doi.org\/10.1007\/s11126-017-9521-z.","journal-title":"Psychiatr Q"},{"issue":"9","key":"7858_CR17","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1017\/s146114571100201x","volume":"15","author":"C Frogley","year":"2012","unstructured":"Frogley C, Taylor D, Dickens G, Picchioni M. A systematic review of the evidence of clozapine\u2019s anti-aggressive effects. Int J Neuropsychopharmacol. 2012;15(9):1351\u201371. https:\/\/doi.org\/10.1017\/s146114571100201x.","journal-title":"Int J Neuropsychopharmacol"},{"key":"7858_CR18","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.schres.2023.11.008","volume":"268","author":"J Faden","year":"2024","unstructured":"Faden J, Citrome L. A systematic review of clozapine for aggression and violence in patients with schizophrenia or schizoaffective disorder. Schizophr Res. 2024;268:265\u201381. https:\/\/doi.org\/10.1016\/j.schres.2023.11.008.","journal-title":"Schizophr Res"},{"key":"7858_CR19","doi-asserted-by":"publisher","first-page":"760181","DOI":"10.3389\/fpsyt.2021.760181","volume":"12","author":"S Hjorth","year":"2021","unstructured":"Hjorth S. The More, the Merrier\u2026 antipsychotic polypharmacy treatment strategies in schizophrenia from a Pharmacology perspective. Front Psychiatry. 2021;12:760181. https:\/\/doi.org\/10.3389\/fpsyt.2021.760181.","journal-title":"Front Psychiatry"},{"issue":"5","key":"7858_CR20","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1093\/ijnp\/pyaa005","volume":"23","author":"E di Giacomo","year":"2020","unstructured":"di Giacomo E, Stefana A, Candini V, Bianconi G, Canal L, Clerici M, Conte G, Ferla MT, Iozzino L, Sbravati G, et al. Prescribing patterns of psychotropic drugs and risk of violent behavior: a prospective, multicenter study in Italy. Int J Neuropsychopharmacol. 2020;23(5):300\u201310. https:\/\/doi.org\/10.1093\/ijnp\/pyaa005.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"4","key":"7858_CR21","doi-asserted-by":"publisher","first-page":"302","DOI":"10.2174\/157015909790031229","volume":"7","author":"R Miller","year":"2009","unstructured":"Miller R. Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: part I. Curr Neuropharmacol. 2009;7(4):302\u201314. https:\/\/doi.org\/10.2174\/157015909790031229.","journal-title":"Curr Neuropharmacol"},{"issue":"4","key":"7858_CR22","doi-asserted-by":"publisher","first-page":"e37234","DOI":"10.7759\/cureus.37234","volume":"15","author":"SU Ajayi","year":"2023","unstructured":"Ajayi SU, Arora P. A survey study on clinicians\u2019 rationale and attitude towards the prescription of antipsychotic polypharmacy in the East Perth metropolitan area in Western Australia. Cureus. 2023;15(4):e37234. https:\/\/doi.org\/10.7759\/cureus.37234.","journal-title":"Cureus"},{"issue":"3","key":"7858_CR23","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1016\/j.sapharm.2021.03.014","volume":"18","author":"ML Nguyen","year":"2022","unstructured":"Nguyen ML, Sunderland B, Lim S, Hattingh L, Chalmers L. A qualitative exploration of factors contributing to non-guideline adherent antipsychotic polypharmacy. Res Social Administrative Pharm. 2022;18(3):2457\u201367. https:\/\/doi.org\/10.1016\/j.sapharm.2021.03.014.","journal-title":"Res Social Administrative Pharm"},{"issue":"1","key":"7858_CR24","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1186\/s12888-024-06004-7","volume":"24","author":"FB Tamene","year":"2024","unstructured":"Tamene FB, Mihiretie EA, Mulugeta A, Kassaye A, Gubae K, Wondm SA. Medication non-adherence and associated factors among peoples with schizophrenia: multicenter cross-sectional study in Northwest Ethiopia. BMC Psychiatry. 2024;24(1):567. https:\/\/doi.org\/10.1186\/s12888-024-06004-7.","journal-title":"BMC Psychiatry"},{"issue":"3","key":"7858_CR25","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1097\/jcp.0000000000001526","volume":"42","author":"E Mutlu","year":"2022","unstructured":"Mutlu E, Kara\u00e7am Do\u011fan M, Ertu\u011frul A, An\u0131l Ya\u011fc\u0131o\u011flu AE. Combination with Long-Acting injectable antipsychotics and utilization of nonstandard formulations as compliance enhancing methods for clozapine users: A systematic review and A case series. J Clin Psychopharmacol. 2022;42(3):298\u2013307. https:\/\/doi.org\/10.1097\/jcp.0000000000001526.","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"7858_CR26","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/yic.0000000000000519","volume":"39","author":"YH Balcioglu","year":"2024","unstructured":"Balcioglu YH, Ozdemir S, Oncu F, Turkcan A. Treatment adherence in forensic patients with schizophrenia spectrum disorders discharged on long-acting injectable antipsychotics: a comparative 3-year mirror-image study. Int Clin Psychopharmacol. 2024;39(4):267\u201375. https:\/\/doi.org\/10.1097\/yic.0000000000000519.","journal-title":"Int Clin Psychopharmacol"},{"key":"7858_CR27","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.schres.2019.05.030","volume":"209","author":"K Matsui","year":"2019","unstructured":"Matsui K, Tokumasu T, Takekita Y, Inada K, Kanazawa T, Kishimoto T, Takasu S, Tani H, Tarutani S, Hashimoto N, et al. Switching to antipsychotic monotherapy vs. staying on antipsychotic polypharmacy in schizophrenia: A systematic review and meta-analysis. Schizophr Res. 2019;209:50\u20137. https:\/\/doi.org\/10.1016\/j.schres.2019.05.030.","journal-title":"Schizophr Res"},{"issue":"1","key":"7858_CR28","doi-asserted-by":"publisher","first-page":"2218654","DOI":"10.1080\/22423982.2023.2218654","volume":"82","author":"S Lassen","year":"2023","unstructured":"Lassen S, Heintz T, Pedersen T, Jentz C, Nathanielsen N, Heilmann P, S\u00f8rensen LU. Nationwide study on antipsychotic polypharmacy among forensic psychiatric patients. Int J Circumpolar Health. 2023;82(1):2218654. https:\/\/doi.org\/10.1080\/22423982.2023.2218654.","journal-title":"Int J Circumpolar Health"},{"key":"7858_CR29","doi-asserted-by":"crossref","unstructured":"Farrell C, Brink J. The prevalence and factors associated with antipsychotic polypharmacy in a forensic psychiatric sample. Front Psychiatry. 2020;11.","DOI":"10.3389\/fpsyt.2020.00263"},{"key":"7858_CR30","doi-asserted-by":"crossref","unstructured":"Mandarelli G, Carabellese F, Di Sciascio G, Catanesi R. Antipsychotic polypharmacy and high-dose antipsychotic regimens in the residential Italian forensic psychiatric population (REMS). Front Psychol. 2022;13.","DOI":"10.3389\/fpsyg.2022.722985"},{"key":"7858_CR31","unstructured":"Kuntz L. Antipsychotic prescriptions and rehospitalizations in a forensic psychiatry sample. Psychiatric Times. 2024;41(12)."},{"issue":"1","key":"7858_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14789949.2017.1332773","volume":"29","author":"N Vasic","year":"2018","unstructured":"Vasic N, Segmiller F, Rees F, J\u00e4ger M, Becker T, Ormanns N, Otte S, Streb J, Dudeck M. Psychopharmacologic treatment of in-patients with schizophrenia: comparing forensic and general psychiatry. J Forensic Psychiatr Psychol. 2018;29(1):1\u201315. https:\/\/doi.org\/10.1080\/14789949.2017.1332773.","journal-title":"J Forensic Psychiatr Psychol"},{"issue":"5","key":"7858_CR33","doi-asserted-by":"publisher","first-page":"383","DOI":"10.2165\/11587810-000000000-00000","volume":"25","author":"TRE Barnes","year":"2011","unstructured":"Barnes TRE, Paton C. Antipsychotic polypharmacy in schizophrenia. CNS Drugs. 2011;25(5):383\u201399. https:\/\/doi.org\/10.2165\/11587810-000000000-00000.","journal-title":"CNS Drugs"},{"key":"7858_CR34","unstructured":"East London N. Prescribing of antipsychotic medication in adult mental health services, including high dose, combined, and PRN. East London NHS; 2022."},{"issue":"11","key":"7858_CR35","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1007\/s40265-021-01556-4","volume":"81","author":"M L\u00e4hteenvuo","year":"2021","unstructured":"L\u00e4hteenvuo M, Tiihonen J. Antipsychotic polypharmacy for the management of schizophrenia: evidence and recommendations. Drugs. 2021;81(11):1273\u201384. https:\/\/doi.org\/10.1007\/s40265-021-01556-4.","journal-title":"Drugs"},{"key":"7858_CR36","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.schres.2023.11.008","volume":"268","author":"J Faden","year":"2024","unstructured":"Faden J, Citrome L. A systematic review of clozapine for aggression and violence in patients with schizophrenia or schizoaffective disorder. Schizophr Res. 2024;268:265\u201381. https:\/\/doi.org\/10.1016\/j.schres.2023.11.008.","journal-title":"Schizophr Res"},{"issue":"4","key":"7858_CR37","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1517\/14740338.2012.683523","volume":"11","author":"JA Gallego","year":"2012","unstructured":"Gallego JA, Nielsen J, De Hert M, Kane JM, Correll CU. Safety and tolerability of antipsychotic polypharmacy. Expert Opin Drug Saf. 2012;11(4):527\u201342. https:\/\/doi.org\/10.1517\/14740338.2012.683523.","journal-title":"Expert Opin Drug Saf"},{"issue":"4","key":"7858_CR38","first-page":"26712","volume":"17","author":"A Madan","year":"2015","unstructured":"Madan A, Oldham JM, Gonzalez S, Fowler JC. Reducing adverse polypharmacy in patients with borderline personality disorder: an empirical case study. Prim Care Companion CNS Disorders. 2015;17(4):26712.","journal-title":"Prim Care Companion CNS Disorders"},{"issue":"4","key":"7858_CR39","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1080\/14999013.2024.2311403","volume":"23","author":"JD Stinson","year":"2024","unstructured":"Stinson JD, LeMay CC, Quinn MA. Adverse childhood Experiences, Suicidality, and aggression as indicators of polypharmacy practice in forensic mental health systems. Int J Forensic Mental Health. 2024;23(4):362\u201374. https:\/\/doi.org\/10.1080\/14999013.2024.2311403.","journal-title":"Int J Forensic Mental Health"},{"issue":"1","key":"7858_CR40","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1186\/s12888-025-06877-2","volume":"25","author":"MM Kaggwa","year":"2025","unstructured":"Kaggwa MM, Davids A, Moulden H, Chaimowitz GA, Mohibi P, Erb B, Olagunju AT. Self-harming behaviors among forensic psychiatric patients who committed violent offences: an exploratory study on the role of circumstances during the index offence and victim characteristics. BMC Psychiatry. 2025;25(1):427. https:\/\/doi.org\/10.1186\/s12888-025-06877-2.","journal-title":"BMC Psychiatry"},{"issue":"6","key":"7858_CR41","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1177\/07067437211023103","volume":"67","author":"G Chaimowitz","year":"2022","unstructured":"Chaimowitz G, Moulden H, Upfold C, Mullally K, Mamak M. The Ontario forensic mental health system: A Population-based review. Can J Psychiatry. 2022;67(6):481\u20139. https:\/\/doi.org\/10.1177\/07067437211023103.","journal-title":"Can J Psychiatry"},{"issue":"1","key":"7858_CR42","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1186\/s12888-023-05394-4","volume":"23","author":"MM Kaggwa","year":"2023","unstructured":"Kaggwa MM, Chaimowitz GA, Erb B, Prat S, Davids A, Moulden H, Robbins A, Bradford J, Mamak M, Olagunju AT. Self-harming behaviors and forensic system-related factors: an analysis of the Ontario review board database. BMC Psychiatry. 2023;23(1):913. https:\/\/doi.org\/10.1186\/s12888-023-05394-4.","journal-title":"BMC Psychiatry"},{"issue":"1","key":"7858_CR43","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1186\/s12888-024-05771-7","volume":"24","author":"MM Kaggwa","year":"2024","unstructured":"Kaggwa MM, Chaimowitz GA, Erb B, Moulden H, Prat S, Davids A, Olagunju AT. Adverse childhood events and self-harming behaviours among individuals in Ontario forensic system: the mediating role of psychopathy. BMC Psychiatry. 2024;24(1):332. https:\/\/doi.org\/10.1186\/s12888-024-05771-7.","journal-title":"BMC Psychiatry"},{"key":"7858_CR44","unstructured":"Mark Mohan K, Bailea E, S\u00e9bastien P, Arianna D, John B, Gary Andrew C. Andrew toyin O: dual harm among patients in the Ontario forensic mental health system. PLoS ONE. 2024."},{"issue":"1","key":"7858_CR45","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s40621-024-00551-z","volume":"11","author":"MM Kaggwa","year":"2024","unstructured":"Kaggwa MM, Davids A, Mohibi P, Erb B, Bradford J, Chaimowitz GA, Olagunju AT. Weapon use during the index offense: a study among forensic psychiatry patients in Ontario, Canada. Injury Epidemiol. 2024;11(1):66. https:\/\/doi.org\/10.1186\/s40621-024-00551-z.","journal-title":"Injury Epidemiol"},{"issue":"1","key":"7858_CR46","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1186\/s12888-025-07431-w","volume":"25","author":"MM Kaggwa","year":"2025","unstructured":"Kaggwa MM, Abaatyo J, Davids A, Brenton L, Komar M, Bradford JMW, Chaimowitz GA, Olagunju AT. Self-harming behaviors among forensic psychiatric patients living with intellectual disability. BMC Psychiatry. 2025;25(1):976. https:\/\/doi.org\/10.1186\/s12888-025-07431-w.","journal-title":"BMC Psychiatry"},{"issue":"1","key":"7858_CR47","doi-asserted-by":"publisher","first-page":"e40","DOI":"10.1017\/S1092852925100242","volume":"30","author":"MM Kaggwa","year":"2025","unstructured":"Kaggwa MM, Abaatyo J, Davids A, Li A, Marsh R, Agboinghale P, Bradford JMW, Chaimowitz GA, Olagunju AT. An exploration of the determinants of risk formulation, care plan and disposition among older adults in the Ontario forensic psychiatry system: implication for practice. CNS Spectr. 2025;30(1):e40. https:\/\/doi.org\/10.1017\/S1092852925100242.","journal-title":"CNS Spectr"},{"issue":"4","key":"7858_CR48","doi-asserted-by":"publisher","first-page":"103365","DOI":"10.1016\/j.arcmed.2025.103365","volume":"57","author":"MM Kaggwa","year":"2026","unstructured":"Kaggwa MM, Abaatyo J, Oladimeji T, Agboinghale P, Bradford JMW, Chaimowitz GA, Olagunju AT. Clozapine augmentation with antipsychotics among patients with schizophrenia spectrum disorders in the Ontario forensic psychiatry system. Arch Med Res. 2026;57(4):103365. https:\/\/doi.org\/10.1016\/j.arcmed.2025.103365.","journal-title":"Arch Med Res"},{"key":"7858_CR49","unstructured":"Richard A-G, Benedict B, Jenny K, Wai, Ip, Angie T. Forensic mental health systems in Ontario versus British Columbia: a comparative issue analysis. Available from: https:\/\/liberalarts.humber.ca\/programs\/research-analyst\/rap-network\/student-showcase\/rap-student-projects-2020-21\/forensic-mental-health-systems-in-ontario-versus-british-columbia-a-comparative-issue-analysis.html. Accessed December 29, 2024."},{"issue":"5","key":"7858_CR50","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1017\/s1092852914000388","volume":"19","author":"DA Morrissette","year":"2014","unstructured":"Morrissette DA, Stahl SM. Treating the violent patient with psychosis or impulsivity utilizing antipsychotic polypharmacy and high-dose monotherapy. CNS Spectr. 2014;19(5):439\u201348. https:\/\/doi.org\/10.1017\/s1092852914000388.","journal-title":"CNS Spectr"},{"key":"7858_CR51","doi-asserted-by":"crossref","unstructured":"Goldberg JF, Ernst CL. Managing the side effects of psychotropic medications. Arlington, VA: American Psychiatric Publishing; 2018.","DOI":"10.1176\/appi.books.9781615378517"},{"issue":"2","key":"7858_CR52","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1089\/cap.2022.0065","volume":"33","author":"A B\u00fcber","year":"2023","unstructured":"B\u00fcber A, Gavcar EG, Ba\u015fay \u00d6, \u00dcnl\u00fc G, Kabuk\u00e7u Ba\u015fay B, \u015eenol H. Prevalence and factors affecting the use of antipsychotics and antipsychotic polypharmacy in a child and adolescent psychiatry inpatient service. J Child Adolesc Psychopharmacol. 2023;33(2):69\u201375. https:\/\/doi.org\/10.1089\/cap.2022.0065.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"5","key":"7858_CR53","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1017\/neu.2022.9","volume":"34","author":"J Bjarke","year":"2022","unstructured":"Bjarke J, Gjerde HN, J\u00f8rgensen HA, Kroken RA, L\u00f8berg E-M, Johnsen E. Akathisia and atypical antipsychotics: relation to suicidality, agitation and depression in a clinical trial. Acta Neuropsychiatrica. 2022;34(5):282\u20138. https:\/\/doi.org\/10.1017\/neu.2022.9.","journal-title":"Acta Neuropsychiatrica"},{"issue":"2","key":"7858_CR54","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1192\/pb.bp.108.024257","volume":"34","author":"J Langan","year":"2010","unstructured":"Langan J, Shajahan P. Antipsychotic polypharmacy: review of mechanisms, mortality and management. Psychiatrist. 2010;34(2):58\u201362. https:\/\/doi.org\/10.1192\/pb.bp.108.024257.","journal-title":"Psychiatrist"},{"issue":"4","key":"7858_CR55","doi-asserted-by":"publisher","first-page":"08","DOI":"10.32996\/jmhs.2022.3.4.2","volume":"3","author":"M Mansoor","year":"2022","unstructured":"Mansoor M, Butt SR, Satnarine T, Ratna P, Sarker A, Ramesh AS, Tello CM, Jamil D, Tran HH-V, Khan S. The association between borderline personality disorder and criminal activity and Self-harm, including suicidal behavior: A systematic review. J Med Health Stud. 2022;3(4):08\u201319.","journal-title":"J Med Health Stud"},{"issue":"8","key":"7858_CR56","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1001\/jama.2023.0589","volume":"329","author":"F Leichsenring","year":"2023","unstructured":"Leichsenring F, Heim N, Leweke F, Spitzer C, Steinert C, Kernberg OF. Borderline personality disorder: A review. JAMA. 2023;329(8):670\u20139. https:\/\/doi.org\/10.1001\/jama.2023.0589.","journal-title":"JAMA"},{"issue":"2","key":"7858_CR57","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s00213-024-06529-5","volume":"241","author":"M Akbari","year":"2024","unstructured":"Akbari M, Jamshidi S, Sheikhi S, Alijani F, Kafshchi P, Taylor D. Aripiprazole and its adverse effects in the form of impulsive-compulsive behaviors: A systematic review of case reports. Psychopharmacology. 2024;241(2):209\u201323. https:\/\/doi.org\/10.1007\/s00213-024-06529-5.","journal-title":"Psychopharmacology"},{"key":"7858_CR58","doi-asserted-by":"crossref","unstructured":"Stefanou M-I, Vittore D, Wolz I, Klingberg S, Wildgruber D. Recurrent episodes of paraphilic behavior possibly associated with olanzapine and aripiprazole treatment in a patient with schizophrenia. Front Psychiatry. 2020;11.","DOI":"10.3389\/fpsyt.2020.00318"},{"issue":"4","key":"7858_CR59","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1002\/hup.1116","volume":"25","author":"S Madhusoodanan","year":"2010","unstructured":"Madhusoodanan S, Parida S, Jimenez C. Hyperprolactinemia associated with psychotropics\u2013a review. Hum Psychopharmacol. 2010;25(4):281\u201397. https:\/\/doi.org\/10.1002\/hup.1116.","journal-title":"Hum Psychopharmacol"},{"issue":"2","key":"7858_CR60","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s40290-023-00462-2","volume":"37","author":"DR Junqueira","year":"2023","unstructured":"Junqueira DR, Bennett D, Huh SY, Casa\u00f1as i Comabella C. Clinical presentations of Drug-Induced hyperprolactinaemia: A literature review. Pharm Med. 2023;37(2):153\u201366. https:\/\/doi.org\/10.1007\/s40290-023-00462-2.","journal-title":"Pharm Med"},{"key":"7858_CR61","doi-asserted-by":"crossref","unstructured":"Anwar S. Hyperprolactinemia as a side effect of using antipsychotics in schizophrenic patients. Surabaya Psychiatry J. 2023;12(2).","DOI":"10.20473\/jps.v12i2.23359"},{"issue":"6","key":"7858_CR62","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s40265-022-01696-1","volume":"82","author":"V Landgren","year":"2022","unstructured":"Landgren V, Savard J, Dhejne C, Jokinen J, Arver S, Seto MC, Rahm C. Pharmacological treatment for pedophilic disorder and compulsive sexual behavior disorder: A review. Drugs. 2022;82(6):663\u201381. https:\/\/doi.org\/10.1007\/s40265-022-01696-1.","journal-title":"Drugs"},{"issue":"1","key":"7858_CR63","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1080\/19585969.2022.2134739","volume":"24","author":"D Turner","year":"2022","unstructured":"Turner D, Briken P, Grubbs J, Malandain L, Mestre-Bach G, Potenza MN, Thibaut F. The world federation of societies of biological psychiatry guidelines on the assessment and Pharmacological treatment of compulsive sexual behaviour disorder. Dialog Clin Neurosci. 2022;24(1):10\u201369. https:\/\/doi.org\/10.1080\/19585969.2022.2134739.","journal-title":"Dialog Clin Neurosci"},{"issue":"1","key":"7858_CR64","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/s41398-022-02027-4","volume":"12","author":"Z Lu","year":"2022","unstructured":"Lu Z, Sun Y, Zhang Y, Chen Y, Guo L, Liao Y, Kang Z, Feng X, Yue W. Pharmacological treatment strategies for antipsychotic-induced hyperprolactinemia: a systematic review and network meta-analysis. Transl Psychiatry. 2022;12(1):267. https:\/\/doi.org\/10.1038\/s41398-022-02027-4.","journal-title":"Transl Psychiatry"},{"key":"7858_CR65","unstructured":"Gilley R. Prevalence and predictors of polypharmacy in adolescents who have engaged in sexually abusive behaviors. 2022."},{"issue":"2","key":"7858_CR66","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.emc.2020.02.002","volume":"38","author":"P Guerrero","year":"2020","unstructured":"Guerrero P, Mycyk MB. Physical and chemical restraints (an update). Emerg Med Clin. 2020;38(2):437\u201351.","journal-title":"Emerg Med Clin"},{"issue":"6","key":"7858_CR67","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1192\/bjp.bp.109.066217","volume":"196","author":"NA Crossley","year":"2010","unstructured":"Crossley NA, Constante M, McGuire P, Power P. Efficacy of atypical v. typical antipsychotics in the treatment of early psychosis: meta-analysis. Br J Psychiatry. 2010;196(6):434\u20139. https:\/\/doi.org\/10.1192\/bjp.bp.109.066217.","journal-title":"Br J Psychiatry"},{"issue":"1","key":"7858_CR68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1185\/03007999709113338","volume":"14","author":"HY Meltzer","year":"1997","unstructured":"Meltzer HY. Treatment-Resistant Schizophrenia - The role of clozapine. Curr Med Res Opin. 1997;14(1):1\u201320. https:\/\/doi.org\/10.1185\/03007999709113338.","journal-title":"Curr Med Res Opin"},{"key":"7858_CR69","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.2165\/11596930-000000000-00000","volume":"25","author":"L Citrome","year":"2011","unstructured":"Citrome L, Volavka J. Pharmacological management of acute and persistent aggression in forensic psychiatry settings. CNS Drugs. 2011;25:1009\u201321.","journal-title":"CNS Drugs"},{"issue":"10","key":"7858_CR70","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1007\/s00213-023-06431-6","volume":"240","author":"J Han","year":"2023","unstructured":"Han J, Allison S, Looi JCL, Chan SKW, Bastiampillai T. A systematic review of the role of clozapine for severe borderline personality disorder. Psychopharmacology. 2023;240(10):2015\u201331. https:\/\/doi.org\/10.1007\/s00213-023-06431-6.","journal-title":"Psychopharmacology"},{"issue":"5","key":"7858_CR71","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1017\/S1092852914000157","volume":"19","author":"D Brown","year":"2014","unstructured":"Brown D, Larkin F, Sengupta S, Romero-Ureclay JL, Ross CC, Gupta N, Vinestock M, Das M. Clozapine: an effective treatment for seriously violent and psychopathic men with antisocial personality disorder in a UK high-security hospital. CNS Spectr. 2014;19(5):391\u2013402. https:\/\/doi.org\/10.1017\/S1092852914000157.","journal-title":"CNS Spectr"},{"issue":"6","key":"7858_CR72","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1176\/appi.ps.002022012","volume":"64","author":"JL G\u00f6ren","year":"2013","unstructured":"G\u00f6ren JL, Meterko M, Williams S, Young GJ, Baker E, Chou CH, Kilbourne AM, Bauer MS. Antipsychotic prescribing pathways, polypharmacy, and clozapine use in treatment of schizophrenia. Psychiatr Serv. 2013;64(6):527\u201333. https:\/\/doi.org\/10.1176\/appi.ps.002022012.","journal-title":"Psychiatr Serv"},{"key":"7858_CR73","doi-asserted-by":"crossref","unstructured":"Shih Y-J, Lin C-H, Chou L-S. The factors associated with clozapine polypharmacy for schizophrenia patients discharged from a large public psychiatric hospital in Taiwan, 2006\u20132021. Medicine (Baltimore). 2024;103(51).","DOI":"10.1097\/MD.0000000000040897"},{"issue":"1","key":"7858_CR74","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1080\/14999013.2004.10471200","volume":"3","author":"M Daffern","year":"2004","unstructured":"Daffern M, Mayer M, Martin T. Environment contributors to aggression in two forensic psychiatric hospitals. Int J Forensic Mental Health. 2004;3(1):105\u201314. https:\/\/doi.org\/10.1080\/14999013.2004.10471200.","journal-title":"Int J Forensic Mental Health"},{"issue":"6","key":"7858_CR75","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.apnu.2015.06.009","volume":"29","author":"H Olsson","year":"2015","unstructured":"Olsson H, Audulv \u00c5, Strand S, Kristiansen L. Reducing or increasing violence in forensic care: A qualitative study of inpatient experiences. Arch Psychiatr Nurs. 2015;29(6):393\u2013400. https:\/\/doi.org\/10.1016\/j.apnu.2015.06.009.","journal-title":"Arch Psychiatr Nurs"},{"issue":"6","key":"7858_CR76","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1192\/bjp.2022.117","volume":"221","author":"M L\u00e4hteenvuo","year":"2022","unstructured":"L\u00e4hteenvuo M, Luykx JJ, Taipale H, Mittendorfer-Rutz E, Tanskanen A, Batalla A, Tiihonen J. Associations between antipsychotic use, substance use and relapse risk in patients with schizophrenia: real-world evidence from two National cohorts. Br J Psychiatry. 2022;221(6):758\u201365. https:\/\/doi.org\/10.1192\/bjp.2022.117.","journal-title":"Br J Psychiatry"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-026-07858-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-026-07858-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-026-07858-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T10:54:20Z","timestamp":1772621660000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12888-026-07858-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":76,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7858"],"URL":"https:\/\/doi.org\/10.1186\/s12888-026-07858-9","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]},"assertion":[{"value":"21 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Hamilton Integrated Research Ethics Board (HiREB) approved the present study, reference number #15564. The ethics committee\/institutional review waived the need for informed consent since the study involved de-identified retrospective data, and individual consent could not practically be obtained. The study was conducted in accordance to the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"224"}}